Terminated PHASE4 INTERVENTIONAL 2-arm NCT01866709

Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia

A Phase 4, Single-center, Prospective, Double-blind, Placebo-controlled, Randomized Study to Investigate the Safety and Efficacy of Sodium Polystyrene Sulfonate (SPS) in Subjects With Hyperkalemia.

Sponsor: ZS Pharma, Inc.

Conditions Hyperkalemia

Interventions Silicified microcrystalline cellulose Sodium polystyrene sulfonate

Updated 7 times since 2017 Last updated: Aug 29, 2014 Started: May 31, 2013 Primary completion: Jul 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Risk/benefit determination showed study revealed negative safety issues.

A PHASE4 clinical study on Hyperkalemia, this trial is terminated or withdrawn. The trial is conducted by ZS Pharma, Inc. and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ZS Pharma, Inc.

Data source: ZS Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edgewater, United States